{"status": "Succeeded", "recognitionResults": [{"page": 1, "clockwiseOrientation": 0.06, "width": 1705, "height": 2240, "unit": "pixel", "lines": [{"boundingBox": [333, 253, 1292, 254, 1291, 284, 332, 283], "text": "Comments on urinary bladder tumors occurred in carcinogenicity studies of NN622", "words": [{"boundingBox": [337, 255, 462, 256, 464, 283, 338, 281], "text": "Comments"}, {"boundingBox": [467, 256, 498, 256, 499, 283, 469, 283], "text": "on"}, {"boundingBox": [503, 256, 586, 257, 587, 284, 504, 283], "text": "urinary"}, {"boundingBox": [591, 257, 678, 257, 679, 284, 593, 284], "text": "bladder"}, {"boundingBox": [683, 257, 765, 257, 765, 285, 684, 284], "text": "tumors"}, {"boundingBox": [770, 257, 870, 256, 871, 285, 771, 285], "text": "occurred"}, {"boundingBox": [875, 256, 901, 256, 901, 285, 876, 285], "text": "in"}, {"boundingBox": [906, 256, 1082, 255, 1083, 285, 906, 285], "text": "carcinogenicity"}, {"boundingBox": [1087, 255, 1169, 255, 1169, 284, 1088, 285], "text": "studies"}, {"boundingBox": [1174, 255, 1198, 254, 1198, 284, 1174, 284], "text": "of"}, {"boundingBox": [1203, 254, 1291, 254, 1291, 284, 1203, 284], "text": "NN622"}]}, {"boundingBox": [1185, 329, 1306, 332, 1305, 360, 1184, 357], "text": "2002/07/24", "words": [{"boundingBox": [1188, 333, 1305, 332, 1304, 361, 1189, 355], "text": "2002/07/24"}]}, {"boundingBox": [997, 372, 1307, 372, 1306, 399, 996, 398], "text": "Drug Safety Research Labs", "words": [{"boundingBox": [999, 372, 1058, 373, 1058, 399, 999, 398], "text": "Drug"}, {"boundingBox": [1067, 373, 1140, 373, 1140, 400, 1067, 399], "text": "Safety"}, {"boundingBox": [1147, 373, 1248, 373, 1248, 400, 1147, 400], "text": "Research"}, {"boundingBox": [1256, 373, 1307, 373, 1307, 399, 1256, 400], "text": "Labs"}]}, {"boundingBox": [315, 446, 1309, 446, 1308, 473, 314, 472], "text": "On 22 July 2002, Novo Nordisk A/S announced that it has decided to suspend the clinical", "words": [{"boundingBox": [318, 446, 352, 446, 352, 473, 319, 473], "text": "On"}, {"boundingBox": [361, 446, 392, 446, 393, 473, 361, 473], "text": "22"}, {"boundingBox": [401, 446, 447, 447, 447, 473, 402, 473], "text": "July"}, {"boundingBox": [457, 447, 519, 447, 519, 473, 458, 473], "text": "2002,"}, {"boundingBox": [524, 447, 584, 447, 584, 473, 524, 473], "text": "Novo"}, {"boundingBox": [591, 447, 675, 447, 675, 474, 591, 473], "text": "Nordisk"}, {"boundingBox": [685, 447, 728, 447, 728, 474, 686, 474], "text": "A/S"}, {"boundingBox": [736, 447, 847, 447, 848, 474, 737, 474], "text": "announced"}, {"boundingBox": [854, 448, 898, 448, 898, 474, 855, 474], "text": "that"}, {"boundingBox": [903, 448, 926, 447, 927, 473, 904, 474], "text": "it"}, {"boundingBox": [931, 447, 973, 447, 974, 473, 932, 473], "text": "has"}, {"boundingBox": [982, 447, 1061, 447, 1062, 473, 983, 473], "text": "decided"}, {"boundingBox": [1067, 447, 1093, 447, 1093, 473, 1067, 473], "text": "to"}, {"boundingBox": [1102, 447, 1186, 447, 1186, 473, 1102, 473], "text": "suspend"}, {"boundingBox": [1193, 447, 1232, 447, 1232, 473, 1193, 473], "text": "the"}, {"boundingBox": [1239, 447, 1309, 447, 1309, 472, 1239, 473], "text": "clinical"}]}, {"boundingBox": [319, 481, 1307, 480, 1308, 508, 319, 509], "text": "development of its dual-acting insulin sensitizer ragaglitazar (NN622). All current clinical trials", "words": [{"boundingBox": [321, 481, 450, 482, 451, 508, 322, 507], "text": "development"}, {"boundingBox": [455, 482, 481, 482, 482, 509, 456, 508], "text": "of"}, {"boundingBox": [486, 482, 519, 482, 520, 509, 487, 509], "text": "its"}, {"boundingBox": [526, 482, 636, 482, 637, 509, 527, 509], "text": "dual-acting"}, {"boundingBox": [642, 482, 712, 482, 713, 510, 642, 509], "text": "insulin"}, {"boundingBox": [719, 482, 815, 482, 816, 510, 720, 510], "text": "sensitizer"}, {"boundingBox": [821, 482, 943, 482, 944, 509, 821, 510], "text": "ragaglitazar"}, {"boundingBox": [948, 482, 1048, 482, 1049, 509, 949, 509], "text": "(NN622)."}, {"boundingBox": [1053, 482, 1091, 482, 1092, 509, 1054, 509], "text": "All"}, {"boundingBox": [1096, 482, 1172, 481, 1173, 508, 1097, 509], "text": "current"}, {"boundingBox": [1177, 481, 1255, 481, 1255, 507, 1178, 508], "text": "clinical"}, {"boundingBox": [1260, 481, 1306, 481, 1307, 507, 1260, 507], "text": "trials"}]}, {"boundingBox": [319, 516, 1305, 517, 1304, 545, 318, 544], "text": "involving ragaglitazar have been stopped and all planned new clinical trials have been postponed,", "words": [{"boundingBox": [319, 517, 415, 517, 415, 544, 320, 544], "text": "involving"}, {"boundingBox": [420, 517, 538, 517, 539, 545, 421, 544], "text": "ragaglitazar"}, {"boundingBox": [543, 517, 593, 518, 593, 545, 544, 545], "text": "have"}, {"boundingBox": [598, 518, 649, 518, 650, 545, 599, 545], "text": "been"}, {"boundingBox": [654, 518, 734, 518, 734, 545, 655, 545], "text": "stopped"}, {"boundingBox": [739, 518, 778, 518, 778, 545, 739, 545], "text": "and"}, {"boundingBox": [783, 518, 811, 518, 812, 545, 784, 545], "text": "all"}, {"boundingBox": [816, 518, 896, 518, 896, 545, 817, 545], "text": "planned"}, {"boundingBox": [901, 518, 943, 518, 944, 545, 901, 545], "text": "new"}, {"boundingBox": [954, 518, 1028, 518, 1028, 545, 954, 545], "text": "clinical"}, {"boundingBox": [1033, 518, 1084, 518, 1085, 545, 1034, 545], "text": "trials"}, {"boundingBox": [1090, 518, 1141, 517, 1141, 545, 1090, 545], "text": "have"}, {"boundingBox": [1146, 517, 1195, 517, 1196, 545, 1146, 545], "text": "been"}, {"boundingBox": [1201, 517, 1305, 517, 1305, 544, 1201, 545], "text": "postponed,"}]}, {"boundingBox": [319, 549, 1310, 550, 1309, 579, 318, 578], "text": "while preliminary data from preclinical studies in rats and mice are being investigated further. Novo", "words": [{"boundingBox": [319, 550, 373, 550, 374, 579, 320, 579], "text": "while"}, {"boundingBox": [378, 550, 498, 551, 499, 579, 379, 579], "text": "preliminary"}, {"boundingBox": [504, 551, 544, 551, 545, 579, 505, 579], "text": "data"}, {"boundingBox": [550, 551, 595, 551, 596, 579, 550, 579], "text": "from"}, {"boundingBox": [601, 551, 707, 552, 708, 579, 602, 579], "text": "preclinical"}, {"boundingBox": [713, 552, 780, 552, 780, 579, 714, 579], "text": "studies"}, {"boundingBox": [785, 552, 806, 552, 807, 579, 786, 579], "text": "in"}, {"boundingBox": [812, 552, 850, 552, 850, 579, 812, 579], "text": "rats"}, {"boundingBox": [856, 552, 892, 552, 892, 579, 856, 579], "text": "and"}, {"boundingBox": [898, 552, 947, 552, 947, 579, 898, 579], "text": "mice"}, {"boundingBox": [953, 552, 983, 552, 983, 579, 953, 579], "text": "are"}, {"boundingBox": [989, 552, 1046, 552, 1046, 579, 989, 579], "text": "being"}, {"boundingBox": [1052, 552, 1172, 551, 1171, 579, 1052, 579], "text": "investigated"}, {"boundingBox": [1177, 551, 1250, 551, 1249, 579, 1177, 579], "text": "further."}, {"boundingBox": [1255, 551, 1310, 550, 1310, 579, 1255, 579], "text": "Novo"}]}, {"boundingBox": [318, 582, 1311, 584, 1310, 614, 317, 611], "text": "Nordisk's decision was taken in response to findings of urinary bladder tumors in one mouse and a", "words": [{"boundingBox": [318, 582, 418, 583, 418, 612, 319, 611], "text": "Nordisk's"}, {"boundingBox": [424, 583, 505, 584, 505, 612, 424, 612], "text": "decision"}, {"boundingBox": [510, 584, 549, 584, 549, 612, 510, 612], "text": "was"}, {"boundingBox": [555, 584, 608, 584, 608, 612, 555, 612], "text": "taken"}, {"boundingBox": [614, 584, 637, 585, 637, 613, 614, 612], "text": "in"}, {"boundingBox": [643, 585, 728, 585, 727, 613, 643, 613], "text": "response"}, {"boundingBox": [733, 585, 756, 585, 756, 613, 733, 613], "text": "to"}, {"boundingBox": [762, 585, 845, 585, 845, 613, 762, 613], "text": "findings"}, {"boundingBox": [851, 585, 872, 586, 871, 613, 850, 613], "text": "of"}, {"boundingBox": [878, 586, 949, 586, 948, 613, 877, 613], "text": "urinary"}, {"boundingBox": [955, 586, 1030, 586, 1029, 613, 954, 613], "text": "bladder"}, {"boundingBox": [1035, 586, 1106, 585, 1106, 613, 1035, 613], "text": "tumors"}, {"boundingBox": [1112, 585, 1133, 585, 1133, 613, 1111, 613], "text": "in"}, {"boundingBox": [1139, 585, 1176, 585, 1175, 613, 1138, 613], "text": "one"}, {"boundingBox": [1181, 585, 1249, 585, 1248, 613, 1181, 613], "text": "mouse"}, {"boundingBox": [1254, 585, 1293, 585, 1292, 613, 1254, 613], "text": "and"}, {"boundingBox": [1299, 585, 1310, 585, 1309, 613, 1298, 613], "text": "a"}]}, {"boundingBox": [318, 617, 1077, 618, 1076, 646, 317, 646], "text": "number of rats treated with ragaglitazar (see the following Website for details).", "words": [{"boundingBox": [318, 618, 394, 618, 394, 646, 318, 646], "text": "number"}, {"boundingBox": [399, 618, 418, 618, 418, 646, 400, 646], "text": "of"}, {"boundingBox": [423, 618, 460, 618, 460, 646, 424, 646], "text": "rats"}, {"boundingBox": [466, 618, 532, 618, 532, 647, 466, 646], "text": "treated"}, {"boundingBox": [538, 618, 580, 618, 581, 647, 538, 647], "text": "with"}, {"boundingBox": [586, 618, 698, 618, 699, 647, 586, 647], "text": "ragaglitazar"}, {"boundingBox": [704, 618, 743, 618, 743, 647, 704, 647], "text": "(see"}, {"boundingBox": [748, 618, 778, 618, 778, 647, 749, 647], "text": "the"}, {"boundingBox": [783, 618, 879, 618, 880, 647, 784, 647], "text": "following"}, {"boundingBox": [885, 618, 961, 618, 961, 646, 885, 647], "text": "Website"}, {"boundingBox": [966, 618, 998, 618, 998, 646, 966, 646], "text": "for"}, {"boundingBox": [1003, 618, 1077, 619, 1077, 646, 1003, 646], "text": "details)."}]}, {"boundingBox": [317, 653, 1301, 654, 1300, 683, 316, 683], "text": "http://www.novonordisk.com/opencms/03_Investors/SEA/English/020722_0.html?cmsframe=content", "words": [{"boundingBox": [317, 654, 1300, 656, 1299, 683, 317, 683], "text": "http://www.novonordisk.com/opencms/03_Investors/SEA/English/020722_0.html?cmsframe=content"}]}, {"boundingBox": [319, 722, 1317, 722, 1316, 754, 318, 753], "text": "Though the detailed information is not available yet, the findings of urinary bladder tumors in NN622", "words": [{"boundingBox": [320, 722, 395, 723, 396, 752, 321, 751], "text": "Though"}, {"boundingBox": [401, 723, 435, 723, 436, 752, 402, 752], "text": "the"}, {"boundingBox": [441, 724, 515, 724, 516, 753, 442, 753], "text": "detailed"}, {"boundingBox": [521, 724, 634, 725, 634, 754, 522, 753], "text": "information"}, {"boundingBox": [639, 725, 657, 725, 657, 754, 640, 754], "text": "is"}, {"boundingBox": [662, 725, 695, 725, 696, 754, 663, 754], "text": "not"}, {"boundingBox": [701, 725, 787, 726, 787, 754, 701, 754], "text": "available"}, {"boundingBox": [792, 726, 829, 726, 829, 754, 793, 754], "text": "yet,"}, {"boundingBox": [834, 726, 865, 726, 866, 754, 835, 754], "text": "the"}, {"boundingBox": [871, 726, 951, 726, 952, 754, 871, 754], "text": "findings"}, {"boundingBox": [957, 726, 978, 726, 978, 754, 957, 754], "text": "of"}, {"boundingBox": [983, 726, 1052, 725, 1053, 753, 984, 754], "text": "urinary"}, {"boundingBox": [1058, 725, 1132, 725, 1133, 753, 1058, 753], "text": "bladder"}, {"boundingBox": [1138, 725, 1207, 724, 1207, 752, 1139, 753], "text": "tumors"}, {"boundingBox": [1212, 724, 1232, 724, 1232, 752, 1213, 752], "text": "in"}, {"boundingBox": [1237, 724, 1316, 723, 1316, 751, 1238, 752], "text": "NN622"}]}, {"boundingBox": [320, 759, 1312, 758, 1313, 787, 321, 788], "text": "seem to be similar to those in Actos. In case of Actos, TAKEDA had conducted several supplemental", "words": [{"boundingBox": [322, 760, 367, 760, 366, 788, 321, 787], "text": "seem"}, {"boundingBox": [375, 760, 393, 760, 392, 788, 373, 788], "text": "to"}, {"boundingBox": [398, 760, 423, 760, 422, 788, 397, 788], "text": "be"}, {"boundingBox": [429, 760, 495, 759, 494, 788, 428, 788], "text": "similar"}, {"boundingBox": [501, 759, 521, 759, 520, 788, 500, 788], "text": "to"}, {"boundingBox": [526, 759, 576, 759, 575, 789, 525, 788], "text": "those"}, {"boundingBox": [582, 759, 603, 759, 602, 789, 581, 789], "text": "in"}, {"boundingBox": [609, 759, 681, 759, 680, 789, 608, 789], "text": "Actos."}, {"boundingBox": [692, 759, 713, 759, 712, 789, 691, 789], "text": "In"}, {"boundingBox": [719, 759, 760, 759, 759, 789, 718, 789], "text": "case"}, {"boundingBox": [766, 759, 787, 759, 786, 789, 765, 789], "text": "of"}, {"boundingBox": [793, 759, 858, 759, 857, 789, 792, 789], "text": "Actos,"}, {"boundingBox": [863, 759, 955, 759, 954, 789, 862, 789], "text": "TAKEDA"}, {"boundingBox": [960, 759, 996, 759, 996, 789, 959, 789], "text": "had"}, {"boundingBox": [1002, 759, 1101, 759, 1100, 788, 1001, 789], "text": "conducted"}, {"boundingBox": [1106, 759, 1175, 759, 1174, 788, 1106, 788], "text": "several"}, {"boundingBox": [1180, 759, 1312, 759, 1311, 787, 1179, 788], "text": "supplemental"}]}, {"boundingBox": [322, 792, 1316, 794, 1315, 824, 321, 822], "text": "studies and has shown the hypothesis that multiple doses of Actos may change urinary nature (PH, ion", "words": [{"boundingBox": [323, 793, 388, 793, 387, 823, 322, 823], "text": "studies"}, {"boundingBox": [393, 793, 427, 793, 426, 823, 393, 823], "text": "and"}, {"boundingBox": [433, 793, 468, 793, 467, 823, 432, 823], "text": "has"}, {"boundingBox": [474, 793, 536, 793, 536, 823, 473, 823], "text": "shown"}, {"boundingBox": [542, 793, 570, 793, 569, 823, 542, 823], "text": "the"}, {"boundingBox": [575, 793, 679, 793, 679, 823, 575, 823], "text": "hypothesis"}, {"boundingBox": [685, 793, 722, 793, 722, 823, 685, 823], "text": "that"}, {"boundingBox": [728, 793, 812, 793, 812, 823, 728, 823], "text": "multiple"}, {"boundingBox": [818, 793, 869, 793, 869, 823, 818, 823], "text": "doses"}, {"boundingBox": [875, 794, 896, 794, 896, 823, 875, 823], "text": "of"}, {"boundingBox": [902, 794, 955, 794, 955, 823, 902, 823], "text": "Actos"}, {"boundingBox": [961, 794, 1004, 794, 1004, 823, 961, 823], "text": "may"}, {"boundingBox": [1010, 794, 1079, 794, 1078, 823, 1010, 823], "text": "change"}, {"boundingBox": [1084, 794, 1155, 795, 1155, 824, 1084, 823], "text": "urinary"}, {"boundingBox": [1161, 795, 1221, 795, 1221, 824, 1160, 824], "text": "nature"}, {"boundingBox": [1227, 795, 1272, 796, 1272, 824, 1227, 824], "text": "(PH,"}, {"boundingBox": [1278, 796, 1315, 796, 1315, 824, 1278, 824], "text": "ion"}]}, {"boundingBox": [322, 828, 1316, 827, 1317, 857, 323, 858], "text": "concentrations, osmolarity and so on) leading to development of microcrystallines or calculi which can", "words": [{"boundingBox": [324, 830, 466, 829, 465, 858, 323, 858], "text": "concentrations,"}, {"boundingBox": [472, 829, 577, 829, 575, 857, 471, 858], "text": "osmolarity"}, {"boundingBox": [582, 829, 618, 829, 616, 857, 581, 857], "text": "and"}, {"boundingBox": [623, 829, 644, 829, 643, 857, 622, 857], "text": "so"}, {"boundingBox": [650, 829, 681, 829, 680, 857, 648, 857], "text": "on)"}, {"boundingBox": [687, 829, 756, 828, 755, 857, 686, 857], "text": "leading"}, {"boundingBox": [762, 828, 786, 828, 785, 857, 760, 857], "text": "to"}, {"boundingBox": [792, 828, 913, 828, 912, 857, 790, 857], "text": "development"}, {"boundingBox": [919, 828, 938, 828, 936, 857, 918, 857], "text": "of"}, {"boundingBox": [943, 828, 1110, 828, 1108, 857, 942, 857], "text": "microcrystallines"}, {"boundingBox": [1115, 828, 1136, 828, 1135, 857, 1114, 857], "text": "or"}, {"boundingBox": [1142, 828, 1207, 829, 1206, 857, 1140, 857], "text": "calculi"}, {"boundingBox": [1213, 829, 1272, 829, 1271, 857, 1211, 857], "text": "which"}, {"boundingBox": [1278, 829, 1317, 829, 1316, 857, 1277, 857], "text": "can"}]}, {"boundingBox": [319, 861, 1308, 860, 1309, 891, 320, 891], "text": "cause damage and regeneration of the bladder epithelium resulting in hyperplasia and tumors in the", "words": [{"boundingBox": [320, 864, 379, 863, 379, 891, 320, 891], "text": "cause"}, {"boundingBox": [385, 863, 460, 863, 460, 891, 385, 891], "text": "damage"}, {"boundingBox": [465, 862, 503, 862, 503, 891, 465, 891], "text": "and"}, {"boundingBox": [508, 862, 633, 862, 633, 890, 508, 891], "text": "regeneration"}, {"boundingBox": [639, 862, 660, 862, 660, 890, 639, 890], "text": "of"}, {"boundingBox": [665, 862, 698, 862, 698, 890, 665, 890], "text": "the"}, {"boundingBox": [703, 862, 778, 861, 778, 890, 703, 890], "text": "bladder"}, {"boundingBox": [783, 861, 885, 861, 885, 890, 783, 890], "text": "epithelium"}, {"boundingBox": [894, 861, 982, 862, 982, 891, 894, 890], "text": "resulting"}, {"boundingBox": [987, 862, 1009, 862, 1009, 891, 987, 891], "text": "in"}, {"boundingBox": [1014, 862, 1128, 862, 1128, 891, 1014, 891], "text": "hyperplasia"}, {"boundingBox": [1134, 862, 1171, 862, 1171, 891, 1134, 891], "text": "and"}, {"boundingBox": [1177, 862, 1248, 863, 1248, 891, 1177, 891], "text": "tumors"}, {"boundingBox": [1254, 863, 1275, 863, 1275, 891, 1253, 891], "text": "in"}, {"boundingBox": [1280, 863, 1309, 863, 1309, 891, 1280, 891], "text": "the"}]}, {"boundingBox": [320, 896, 1316, 897, 1315, 925, 319, 924], "text": "bladder epithelium in rats. These urinary changes and tumorigenic response of the urinary bladder", "words": [{"boundingBox": [320, 897, 396, 897, 397, 924, 321, 924], "text": "bladder"}, {"boundingBox": [402, 897, 503, 897, 503, 925, 402, 924], "text": "epithelium"}, {"boundingBox": [511, 897, 533, 897, 533, 925, 512, 925], "text": "in"}, {"boundingBox": [538, 897, 591, 897, 592, 925, 539, 925], "text": "rats."}, {"boundingBox": [605, 897, 664, 897, 665, 925, 606, 925], "text": "These"}, {"boundingBox": [669, 897, 742, 897, 743, 925, 670, 925], "text": "urinary"}, {"boundingBox": [747, 897, 827, 897, 828, 926, 748, 925], "text": "changes"}, {"boundingBox": [832, 897, 869, 897, 870, 926, 833, 926], "text": "and"}, {"boundingBox": [875, 897, 994, 897, 995, 926, 876, 926], "text": "tumorigenic"}, {"boundingBox": [999, 897, 1087, 897, 1089, 925, 1000, 926], "text": "response"}, {"boundingBox": [1093, 897, 1116, 897, 1117, 925, 1094, 925], "text": "of"}, {"boundingBox": [1121, 897, 1153, 897, 1154, 925, 1122, 925], "text": "the"}, {"boundingBox": [1158, 897, 1231, 897, 1232, 925, 1159, 925], "text": "urinary"}, {"boundingBox": [1236, 897, 1314, 897, 1316, 925, 1238, 925], "text": "bladder"}]}, {"boundingBox": [316, 933, 1309, 934, 1308, 961, 315, 960], "text": "are specific to rodent, in particular rats, and probably have no relevance for other species including", "words": [{"boundingBox": [319, 934, 353, 934, 353, 960, 320, 960], "text": "are", "confidence": "Low"}, {"boundingBox": [358, 934, 435, 934, 436, 960, 358, 960], "text": "specific"}, {"boundingBox": [440, 934, 462, 934, 463, 961, 441, 960], "text": "to"}, {"boundingBox": [467, 934, 540, 934, 540, 961, 468, 961], "text": "rodent,"}, {"boundingBox": [545, 934, 567, 934, 567, 961, 545, 961], "text": "in"}, {"boundingBox": [572, 934, 666, 934, 667, 961, 572, 961], "text": "particular"}, {"boundingBox": [671, 934, 717, 934, 717, 961, 672, 961], "text": "rats,"}, {"boundingBox": [722, 934, 759, 934, 760, 961, 722, 961], "text": "and"}, {"boundingBox": [764, 934, 853, 934, 854, 962, 765, 961], "text": "probably"}, {"boundingBox": [858, 934, 907, 934, 908, 962, 859, 962], "text": "have"}, {"boundingBox": [912, 934, 939, 934, 940, 962, 913, 962], "text": "no"}, {"boundingBox": [944, 934, 1040, 934, 1041, 962, 945, 962], "text": "relevance"}, {"boundingBox": [1045, 934, 1079, 934, 1080, 962, 1046, 962], "text": "for"}, {"boundingBox": [1084, 934, 1136, 934, 1137, 962, 1085, 962], "text": "other"}, {"boundingBox": [1141, 934, 1213, 934, 1215, 962, 1142, 962], "text": "species"}, {"boundingBox": [1218, 934, 1308, 934, 1309, 961, 1220, 962], "text": "including"}]}, {"boundingBox": [320, 965, 419, 970, 417, 996, 318, 991], "text": "humans.", "words": [{"boundingBox": [320, 966, 413, 970, 414, 996, 320, 993], "text": "humans."}]}, {"boundingBox": [422, 968, 1314, 967, 1315, 995, 422, 996], "text": "It is noteworthy that Actos and its metabolites are not genotoxic and have not direct", "words": [{"boundingBox": [437, 968, 455, 968, 456, 996, 437, 995], "text": "It"}, {"boundingBox": [461, 968, 483, 968, 483, 996, 461, 996], "text": "is"}, {"boundingBox": [488, 968, 603, 969, 604, 996, 489, 996], "text": "noteworthy"}, {"boundingBox": [608, 969, 652, 969, 653, 996, 609, 996], "text": "that"}, {"boundingBox": [658, 969, 718, 970, 718, 996, 658, 996], "text": "Actos"}, {"boundingBox": [723, 970, 762, 970, 762, 996, 724, 996], "text": "and"}, {"boundingBox": [767, 970, 796, 970, 797, 996, 768, 996], "text": "its"}, {"boundingBox": [802, 970, 918, 970, 919, 996, 802, 996], "text": "metabolites"}, {"boundingBox": [924, 970, 957, 970, 958, 996, 925, 996], "text": "are"}, {"boundingBox": [962, 970, 1000, 970, 1001, 996, 963, 996], "text": "not"}, {"boundingBox": [1006, 970, 1106, 969, 1107, 995, 1007, 996], "text": "genotoxic"}, {"boundingBox": [1112, 969, 1150, 969, 1151, 995, 1113, 995], "text": "and"}, {"boundingBox": [1155, 969, 1206, 969, 1208, 995, 1157, 995], "text": "have"}, {"boundingBox": [1212, 969, 1252, 968, 1253, 995, 1213, 995], "text": "not"}, {"boundingBox": [1257, 968, 1314, 968, 1315, 994, 1259, 995], "text": "direct"}]}, {"boundingBox": [321, 1001, 775, 1003, 774, 1030, 320, 1029], "text": "proliferative effects on the bladder epithelium.", "words": [{"boundingBox": [321, 1003, 440, 1003, 441, 1030, 321, 1029], "text": "proliferative"}, {"boundingBox": [446, 1003, 510, 1003, 511, 1030, 446, 1030], "text": "effects"}, {"boundingBox": [515, 1003, 539, 1003, 540, 1030, 516, 1030], "text": "on"}, {"boundingBox": [545, 1003, 574, 1003, 575, 1030, 545, 1030], "text": "the"}, {"boundingBox": [579, 1003, 654, 1003, 655, 1030, 580, 1030], "text": "bladder"}, {"boundingBox": [659, 1004, 774, 1005, 774, 1031, 660, 1030], "text": "epithelium."}]}, {"boundingBox": [323, 1032, 1315, 1036, 1314, 1066, 322, 1063], "text": "FDA-CDER thinks that our hypothesis is plausible but not fully acceptable (see the Website for", "words": [{"boundingBox": [323, 1033, 442, 1035, 443, 1062, 324, 1060], "text": "FDA-CDER"}, {"boundingBox": [451, 1035, 516, 1036, 517, 1063, 451, 1062], "text": "thinks"}, {"boundingBox": [522, 1036, 564, 1037, 565, 1063, 522, 1063], "text": "that"}, {"boundingBox": [569, 1037, 605, 1037, 606, 1064, 570, 1064], "text": "our"}, {"boundingBox": [610, 1037, 720, 1038, 721, 1065, 611, 1064], "text": "hypothesis"}, {"boundingBox": [725, 1038, 745, 1038, 746, 1065, 726, 1065], "text": "is"}, {"boundingBox": [750, 1038, 844, 1038, 845, 1065, 751, 1065], "text": "plausible"}, {"boundingBox": [849, 1038, 885, 1039, 885, 1066, 850, 1066], "text": "but"}, {"boundingBox": [890, 1039, 929, 1038, 930, 1066, 891, 1066], "text": "not"}, {"boundingBox": [934, 1038, 984, 1038, 985, 1066, 935, 1066], "text": "fully"}, {"boundingBox": [989, 1038, 1097, 1038, 1098, 1066, 990, 1066], "text": "acceptable"}, {"boundingBox": [1103, 1038, 1147, 1038, 1148, 1066, 1103, 1066], "text": "(see"}, {"boundingBox": [1152, 1037, 1189, 1037, 1190, 1066, 1153, 1066], "text": "the"}, {"boundingBox": [1195, 1037, 1276, 1036, 1277, 1065, 1195, 1066], "text": "Website"}, {"boundingBox": [1281, 1036, 1313, 1036, 1314, 1065, 1282, 1065], "text": "for"}]}, {"boundingBox": [322, 1069, 396, 1071, 395, 1099, 322, 1098], "text": "details).", "words": [{"boundingBox": [323, 1068, 395, 1069, 394, 1098, 323, 1097], "text": "details)."}]}, {"boundingBox": [314, 1105, 874, 1106, 874, 1136, 313, 1135], "text": "http://www.fda.gov/cder/foi/nda/99/021073A_Actos.htm", "words": [{"boundingBox": [318, 1106, 867, 1106, 868, 1136, 319, 1135], "text": "http://www.fda.gov/cder/foi/nda/99/021073A_Actos.htm", "confidence": "Low"}]}, {"boundingBox": [321, 1176, 1315, 1176, 1314, 1205, 320, 1204], "text": "In addition, it is well known that carbonic anhydrase inhibitors such as acetazolamide can develop", "words": [{"boundingBox": [321, 1176, 344, 1177, 345, 1204, 322, 1203], "text": "In"}, {"boundingBox": [350, 1177, 439, 1177, 439, 1204, 350, 1204], "text": "addition,"}, {"boundingBox": [444, 1177, 462, 1177, 462, 1205, 444, 1204], "text": "it"}, {"boundingBox": [467, 1178, 488, 1178, 489, 1205, 467, 1205], "text": "is"}, {"boundingBox": [494, 1178, 538, 1178, 538, 1205, 494, 1205], "text": "well"}, {"boundingBox": [543, 1178, 613, 1178, 613, 1205, 544, 1205], "text": "known"}, {"boundingBox": [618, 1178, 659, 1179, 659, 1206, 618, 1205], "text": "that"}, {"boundingBox": [664, 1179, 749, 1179, 749, 1206, 664, 1206], "text": "carbonic"}, {"boundingBox": [755, 1179, 856, 1179, 856, 1206, 755, 1206], "text": "anhydrase"}, {"boundingBox": [861, 1179, 959, 1179, 959, 1206, 861, 1206], "text": "inhibitors"}, {"boundingBox": [964, 1179, 1010, 1179, 1010, 1206, 964, 1206], "text": "such"}, {"boundingBox": [1016, 1179, 1040, 1179, 1040, 1205, 1015, 1206], "text": "as"}, {"boundingBox": [1046, 1179, 1188, 1178, 1187, 1205, 1045, 1205], "text": "acetazolamide"}, {"boundingBox": [1193, 1178, 1230, 1178, 1230, 1204, 1193, 1205], "text": "can"}, {"boundingBox": [1239, 1178, 1316, 1178, 1315, 1204, 1239, 1204], "text": "develop"}]}, {"boundingBox": [315, 1210, 1317, 1211, 1316, 1242, 314, 1241], "text": "microcrystallines or calculi by changing urinary pH resulting in urinary bladder hyperplasia and", "words": [{"boundingBox": [319, 1211, 494, 1212, 494, 1240, 319, 1238], "text": "microcrystallines"}, {"boundingBox": [499, 1212, 525, 1212, 525, 1240, 499, 1240], "text": "or"}, {"boundingBox": [530, 1212, 599, 1212, 599, 1241, 530, 1241], "text": "calculi"}, {"boundingBox": [605, 1213, 636, 1213, 636, 1241, 605, 1241], "text": "by"}, {"boundingBox": [641, 1213, 734, 1213, 735, 1242, 641, 1241], "text": "changing"}, {"boundingBox": [740, 1213, 816, 1213, 816, 1242, 740, 1242], "text": "urinary"}, {"boundingBox": [821, 1213, 852, 1213, 852, 1242, 821, 1242], "text": "pH"}, {"boundingBox": [863, 1213, 953, 1213, 953, 1242, 863, 1242], "text": "resulting"}, {"boundingBox": [958, 1213, 982, 1212, 982, 1242, 958, 1242], "text": "in"}, {"boundingBox": [987, 1212, 1063, 1212, 1064, 1241, 988, 1242], "text": "urinary"}, {"boundingBox": [1069, 1212, 1147, 1212, 1147, 1241, 1069, 1241], "text": "bladder"}, {"boundingBox": [1152, 1212, 1271, 1211, 1272, 1239, 1152, 1241], "text": "hyperplasia"}, {"boundingBox": [1276, 1211, 1316, 1211, 1317, 1239, 1277, 1239], "text": "and"}]}, {"boundingBox": [321, 1245, 1317, 1244, 1318, 1275, 322, 1276], "text": "tumors in rodents (not in human). Actos and its metabolite M-V have weak inhibitory effects on", "words": [{"boundingBox": [322, 1248, 390, 1248, 390, 1275, 322, 1275], "text": "tumors"}, {"boundingBox": [395, 1248, 420, 1247, 420, 1275, 395, 1275], "text": "in"}, {"boundingBox": [425, 1247, 500, 1247, 500, 1275, 425, 1275], "text": "rodents"}, {"boundingBox": [505, 1247, 549, 1246, 549, 1276, 505, 1275], "text": "(not"}, {"boundingBox": [554, 1246, 577, 1246, 577, 1276, 554, 1276], "text": "in"}, {"boundingBox": [582, 1246, 673, 1246, 673, 1276, 582, 1276], "text": "human)."}, {"boundingBox": [687, 1246, 746, 1245, 747, 1276, 687, 1276], "text": "Actos"}, {"boundingBox": [752, 1245, 788, 1245, 788, 1276, 752, 1276], "text": "and"}, {"boundingBox": [794, 1245, 822, 1245, 822, 1276, 794, 1276], "text": "its"}, {"boundingBox": [827, 1245, 933, 1245, 934, 1276, 827, 1276], "text": "metabolite"}, {"boundingBox": [939, 1245, 986, 1245, 986, 1276, 939, 1276], "text": "M-V"}, {"boundingBox": [991, 1245, 1043, 1245, 1044, 1276, 991, 1276], "text": "have"}, {"boundingBox": [1049, 1245, 1103, 1245, 1103, 1276, 1049, 1276], "text": "weak"}, {"boundingBox": [1108, 1245, 1209, 1246, 1210, 1276, 1108, 1276], "text": "inhibitory"}, {"boundingBox": [1215, 1246, 1281, 1246, 1281, 1276, 1215, 1276], "text": "effects"}, {"boundingBox": [1286, 1246, 1316, 1246, 1316, 1276, 1286, 1276], "text": "on"}]}, {"boundingBox": [322, 1279, 1316, 1278, 1317, 1310, 323, 1311], "text": "carbonic anhydrase in the kidney and urinary bladder. We thought that this inhibitory effect of Actos", "words": [{"boundingBox": [324, 1283, 404, 1282, 404, 1310, 323, 1310], "text": "carbonic"}, {"boundingBox": [410, 1282, 509, 1281, 509, 1310, 409, 1310], "text": "anhydrase"}, {"boundingBox": [515, 1281, 534, 1281, 534, 1310, 514, 1310], "text": "in"}, {"boundingBox": [539, 1281, 569, 1281, 569, 1310, 539, 1310], "text": "the"}, {"boundingBox": [574, 1281, 643, 1280, 642, 1310, 574, 1310], "text": "kidney"}, {"boundingBox": [648, 1280, 683, 1280, 683, 1310, 648, 1310], "text": "and"}, {"boundingBox": [688, 1280, 757, 1279, 756, 1310, 688, 1310], "text": "urinary"}, {"boundingBox": [762, 1279, 853, 1279, 853, 1310, 761, 1310], "text": "bladder."}, {"boundingBox": [867, 1279, 897, 1279, 897, 1310, 867, 1310], "text": "We"}, {"boundingBox": [902, 1279, 978, 1279, 977, 1311, 902, 1310], "text": "thought"}, {"boundingBox": [983, 1279, 1018, 1279, 1018, 1311, 982, 1311], "text": "that"}, {"boundingBox": [1023, 1279, 1060, 1279, 1060, 1311, 1023, 1311], "text": "this"}, {"boundingBox": [1066, 1279, 1162, 1280, 1161, 1311, 1065, 1311], "text": "inhibitory"}, {"boundingBox": [1167, 1280, 1223, 1280, 1223, 1311, 1167, 1311], "text": "effect"}, {"boundingBox": [1229, 1280, 1251, 1280, 1251, 1311, 1228, 1311], "text": "of"}, {"boundingBox": [1257, 1280, 1316, 1281, 1316, 1311, 1256, 1311], "text": "Actos"}]}, {"boundingBox": [316, 1314, 1316, 1313, 1317, 1343, 317, 1344], "text": "may be involved in the mechanism of the urinary bladder tumor, but Dr. Cohen, who wrote \"White", "words": [{"boundingBox": [319, 1316, 363, 1316, 363, 1344, 319, 1345], "text": "may"}, {"boundingBox": [369, 1316, 395, 1316, 395, 1344, 369, 1344], "text": "be"}, {"boundingBox": [401, 1316, 489, 1315, 489, 1344, 401, 1344], "text": "involved"}, {"boundingBox": [495, 1315, 517, 1315, 517, 1344, 495, 1344], "text": "in"}, {"boundingBox": [523, 1315, 553, 1315, 553, 1344, 523, 1344], "text": "the"}, {"boundingBox": [558, 1315, 669, 1314, 669, 1343, 558, 1344], "text": "mechanism"}, {"boundingBox": [678, 1314, 701, 1314, 701, 1343, 678, 1343], "text": "of"}, {"boundingBox": [707, 1314, 738, 1314, 738, 1343, 706, 1343], "text": "the"}, {"boundingBox": [744, 1314, 815, 1314, 815, 1343, 744, 1343], "text": "urinary"}, {"boundingBox": [821, 1314, 896, 1314, 895, 1343, 820, 1343], "text": "bladder"}, {"boundingBox": [901, 1314, 967, 1314, 966, 1343, 901, 1343], "text": "tumor,"}, {"boundingBox": [973, 1314, 1006, 1314, 1006, 1344, 972, 1343], "text": "but"}, {"boundingBox": [1012, 1314, 1046, 1314, 1045, 1344, 1011, 1344], "text": "Dr."}, {"boundingBox": [1051, 1314, 1123, 1314, 1122, 1344, 1051, 1344], "text": "Cohen,"}, {"boundingBox": [1128, 1314, 1173, 1315, 1172, 1344, 1127, 1344], "text": "who"}, {"boundingBox": [1179, 1315, 1235, 1315, 1234, 1344, 1178, 1344], "text": "wrote"}, {"boundingBox": [1241, 1315, 1316, 1315, 1315, 1345, 1240, 1344], "text": "\"White"}]}, {"boundingBox": [322, 1348, 1311, 1349, 1310, 1380, 321, 1379], "text": "Paper\" for Actos as an expert of this area, had negative impression about its involvement. An effect", "words": [{"boundingBox": [322, 1349, 386, 1349, 388, 1380, 325, 1380], "text": "Paper\""}, {"boundingBox": [392, 1349, 422, 1349, 424, 1380, 394, 1380], "text": "for"}, {"boundingBox": [428, 1349, 486, 1350, 487, 1379, 430, 1379], "text": "Actos"}, {"boundingBox": [492, 1350, 512, 1350, 513, 1379, 493, 1379], "text": "as"}, {"boundingBox": [518, 1350, 543, 1350, 544, 1379, 520, 1379], "text": "an"}, {"boundingBox": [549, 1350, 610, 1350, 611, 1379, 550, 1379], "text": "expert"}, {"boundingBox": [616, 1350, 636, 1350, 637, 1379, 617, 1379], "text": "of"}, {"boundingBox": [642, 1350, 677, 1350, 678, 1379, 644, 1379], "text": "this"}, {"boundingBox": [683, 1350, 730, 1350, 731, 1379, 684, 1379], "text": "area,"}, {"boundingBox": [736, 1350, 771, 1350, 772, 1379, 737, 1379], "text": "had"}, {"boundingBox": [777, 1350, 861, 1350, 861, 1379, 778, 1379], "text": "negative"}, {"boundingBox": [867, 1350, 975, 1350, 975, 1380, 867, 1379], "text": "impression"}, {"boundingBox": [981, 1350, 1034, 1350, 1034, 1380, 981, 1380], "text": "about"}, {"boundingBox": [1040, 1350, 1064, 1350, 1064, 1380, 1040, 1380], "text": "its"}, {"boundingBox": [1071, 1350, 1211, 1350, 1211, 1380, 1070, 1380], "text": "involvement."}, {"boundingBox": [1221, 1350, 1252, 1350, 1251, 1381, 1221, 1381], "text": "An"}, {"boundingBox": [1258, 1350, 1311, 1349, 1310, 1381, 1257, 1381], "text": "effect"}]}, {"boundingBox": [322, 1384, 1315, 1385, 1314, 1415, 321, 1414], "text": "of NN622 on carbonic anhydrase will be checked soon by Dr. Odaka (Pharmacology Research", "words": [{"boundingBox": [322, 1386, 347, 1386, 348, 1413, 323, 1413], "text": "of"}, {"boundingBox": [352, 1386, 431, 1386, 432, 1414, 354, 1413], "text": "NN622"}, {"boundingBox": [437, 1386, 467, 1386, 468, 1414, 437, 1414], "text": "on"}, {"boundingBox": [474, 1386, 564, 1385, 564, 1414, 475, 1414], "text": "carbonic"}, {"boundingBox": [569, 1385, 673, 1385, 673, 1414, 569, 1414], "text": "anhydrase"}, {"boundingBox": [678, 1385, 721, 1385, 721, 1414, 678, 1414], "text": "will"}, {"boundingBox": [726, 1385, 757, 1385, 756, 1414, 726, 1414], "text": "be"}, {"boundingBox": [762, 1385, 848, 1385, 847, 1414, 762, 1414], "text": "checked"}, {"boundingBox": [853, 1385, 904, 1385, 902, 1414, 852, 1414], "text": "soon"}, {"boundingBox": [909, 1385, 941, 1385, 940, 1415, 908, 1414], "text": "by"}, {"boundingBox": [947, 1385, 984, 1385, 983, 1415, 945, 1415], "text": "Dr."}, {"boundingBox": [989, 1385, 1057, 1385, 1056, 1415, 988, 1415], "text": "Odaka"}, {"boundingBox": [1063, 1385, 1217, 1385, 1214, 1415, 1061, 1415], "text": "(Pharmacology"}, {"boundingBox": [1222, 1385, 1313, 1385, 1310, 1416, 1220, 1415], "text": "Research"}]}, {"boundingBox": [321, 1419, 423, 1422, 422, 1448, 320, 1445], "text": "Division).", "words": [{"boundingBox": [321, 1420, 421, 1422, 422, 1448, 322, 1447], "text": "Division)."}]}, {"boundingBox": [319, 1490, 934, 1489, 935, 1517, 320, 1518], "text": "We now have both optimistic and pessimistic views as follows:", "words": [{"boundingBox": [322, 1491, 351, 1491, 352, 1517, 323, 1517], "text": "We"}, {"boundingBox": [356, 1491, 399, 1492, 400, 1518, 357, 1517], "text": "now"}, {"boundingBox": [404, 1492, 453, 1492, 454, 1518, 405, 1518], "text": "have"}, {"boundingBox": [458, 1492, 503, 1493, 504, 1518, 459, 1518], "text": "both"}, {"boundingBox": [508, 1493, 605, 1493, 605, 1519, 509, 1518], "text": "optimistic"}, {"boundingBox": [610, 1493, 645, 1493, 645, 1519, 611, 1519], "text": "and"}, {"boundingBox": [650, 1493, 759, 1492, 759, 1518, 650, 1519], "text": "pessimistic"}, {"boundingBox": [764, 1492, 819, 1492, 819, 1518, 764, 1518], "text": "views"}, {"boundingBox": [824, 1492, 847, 1491, 847, 1518, 825, 1518], "text": "as"}, {"boundingBox": [852, 1491, 935, 1490, 935, 1517, 852, 1518], "text": "follows:"}]}, {"boundingBox": [324, 1524, 513, 1525, 512, 1553, 323, 1552], "text": "[Optimistic views]", "words": [{"boundingBox": [324, 1525, 440, 1526, 441, 1553, 325, 1553], "text": "[Optimistic"}, {"boundingBox": [445, 1526, 512, 1526, 513, 1552, 446, 1553], "text": "views]"}]}, {"boundingBox": [318, 1559, 1246, 1558, 1247, 1586, 318, 1587], "text": "Urinary microcrystallines or calculi will be found in the carcinogenicity study of NN622 in rats.", "words": [{"boundingBox": [320, 1559, 395, 1560, 395, 1587, 321, 1587], "text": "Urinary"}, {"boundingBox": [400, 1560, 569, 1560, 569, 1586, 400, 1587], "text": "microcrystallines"}, {"boundingBox": [575, 1560, 595, 1561, 595, 1586, 575, 1586], "text": "or"}, {"boundingBox": [600, 1561, 666, 1561, 665, 1586, 600, 1586], "text": "calculi"}, {"boundingBox": [671, 1561, 707, 1561, 707, 1586, 671, 1586], "text": "will"}, {"boundingBox": [713, 1561, 736, 1561, 736, 1586, 713, 1586], "text": "be"}, {"boundingBox": [742, 1561, 798, 1561, 798, 1586, 742, 1586], "text": "found"}, {"boundingBox": [804, 1561, 824, 1561, 823, 1586, 803, 1586], "text": "in"}, {"boundingBox": [829, 1561, 860, 1561, 860, 1586, 829, 1586], "text": "the"}, {"boundingBox": [866, 1561, 1013, 1560, 1012, 1586, 865, 1586], "text": "carcinogenicity"}, {"boundingBox": [1018, 1560, 1071, 1560, 1070, 1586, 1017, 1586], "text": "study"}, {"boundingBox": [1076, 1560, 1096, 1560, 1096, 1586, 1076, 1586], "text": "of"}, {"boundingBox": [1102, 1560, 1173, 1560, 1172, 1587, 1101, 1586], "text": "NN622"}, {"boundingBox": [1178, 1560, 1198, 1560, 1197, 1587, 1177, 1587], "text": "in"}, {"boundingBox": [1204, 1560, 1247, 1559, 1246, 1587, 1203, 1587], "text": "rats."}]}, {"boundingBox": [320, 1593, 1222, 1592, 1223, 1620, 321, 1621], "text": "Dr. Odaka will find that NN622 has inhibitory effects on carbonic anhydrase as well as Actos.", "words": [{"boundingBox": [321, 1594, 352, 1594, 351, 1621, 321, 1621], "text": "Dr."}, {"boundingBox": [357, 1594, 422, 1594, 421, 1621, 356, 1621], "text": "Odaka"}, {"boundingBox": [427, 1594, 466, 1594, 466, 1621, 427, 1621], "text": "will"}, {"boundingBox": [471, 1594, 511, 1594, 510, 1621, 471, 1621], "text": "find"}, {"boundingBox": [516, 1594, 552, 1594, 551, 1621, 515, 1621], "text": "that"}, {"boundingBox": [557, 1594, 628, 1593, 628, 1621, 556, 1621], "text": "NN622"}, {"boundingBox": [634, 1593, 666, 1593, 666, 1621, 633, 1621], "text": "has"}, {"boundingBox": [671, 1593, 767, 1593, 767, 1621, 671, 1621], "text": "inhibitory"}, {"boundingBox": [772, 1593, 837, 1593, 837, 1621, 772, 1621], "text": "effects"}, {"boundingBox": [842, 1593, 868, 1593, 867, 1621, 842, 1621], "text": "on"}, {"boundingBox": [873, 1593, 955, 1593, 955, 1621, 872, 1621], "text": "carbonic"}, {"boundingBox": [960, 1593, 1059, 1594, 1059, 1621, 960, 1621], "text": "anhydrase"}, {"boundingBox": [1064, 1594, 1085, 1594, 1084, 1621, 1064, 1621], "text": "as"}, {"boundingBox": [1090, 1594, 1132, 1594, 1132, 1621, 1090, 1621], "text": "well"}, {"boundingBox": [1138, 1594, 1158, 1594, 1158, 1620, 1137, 1621], "text": "as"}, {"boundingBox": [1163, 1594, 1223, 1594, 1223, 1620, 1163, 1620], "text": "Actos."}]}, {"boundingBox": [320, 1626, 841, 1628, 841, 1658, 319, 1656], "text": "Novo Nordisk will think the same hypothesis as ours.", "words": [{"boundingBox": [321, 1628, 375, 1628, 374, 1656, 320, 1656], "text": "Novo"}, {"boundingBox": [380, 1628, 460, 1628, 460, 1656, 380, 1656], "text": "Nordisk"}, {"boundingBox": [466, 1628, 503, 1628, 503, 1656, 465, 1656], "text": "will"}, {"boundingBox": [509, 1628, 559, 1628, 559, 1656, 508, 1656], "text": "think"}, {"boundingBox": [565, 1628, 594, 1628, 594, 1657, 564, 1656], "text": "the"}, {"boundingBox": [600, 1628, 648, 1629, 648, 1657, 599, 1657], "text": "same"}, {"boundingBox": [654, 1629, 758, 1629, 758, 1658, 653, 1657], "text": "hypothesis"}, {"boundingBox": [764, 1629, 784, 1630, 784, 1658, 763, 1658], "text": "as"}, {"boundingBox": [790, 1630, 840, 1630, 840, 1658, 789, 1658], "text": "ours."}]}, {"boundingBox": [322, 1662, 1318, 1662, 1317, 1693, 321, 1692], "text": "There will be no bladder tumors in a carcinogenicity study of TAK-559 in rats (to be necropsied on", "words": [{"boundingBox": [324, 1662, 379, 1662, 379, 1691, 324, 1691], "text": "There"}, {"boundingBox": [385, 1662, 426, 1663, 426, 1692, 385, 1691], "text": "will"}, {"boundingBox": [431, 1663, 456, 1663, 456, 1692, 431, 1692], "text": "be"}, {"boundingBox": [462, 1664, 489, 1664, 489, 1692, 462, 1692], "text": "no"}, {"boundingBox": [495, 1664, 570, 1665, 570, 1693, 495, 1692], "text": "bladder"}, {"boundingBox": [575, 1665, 645, 1665, 645, 1693, 576, 1693], "text": "tumors"}, {"boundingBox": [650, 1665, 672, 1666, 672, 1693, 651, 1693], "text": "in"}, {"boundingBox": [677, 1666, 691, 1666, 691, 1693, 677, 1693], "text": "a"}, {"boundingBox": [697, 1666, 846, 1667, 847, 1693, 697, 1693], "text": "carcinogenicity"}, {"boundingBox": [852, 1667, 906, 1667, 906, 1693, 852, 1693], "text": "study"}, {"boundingBox": [912, 1667, 937, 1667, 937, 1693, 912, 1693], "text": "of"}, {"boundingBox": [942, 1667, 1033, 1667, 1033, 1692, 943, 1693], "text": "TAK-559"}, {"boundingBox": [1039, 1667, 1060, 1667, 1060, 1692, 1039, 1692], "text": "in"}, {"boundingBox": [1065, 1667, 1102, 1667, 1102, 1692, 1066, 1692], "text": "rats"}, {"boundingBox": [1108, 1667, 1138, 1667, 1139, 1691, 1108, 1692], "text": "(to"}, {"boundingBox": [1144, 1667, 1167, 1666, 1168, 1691, 1145, 1691], "text": "be"}, {"boundingBox": [1173, 1666, 1281, 1666, 1281, 1689, 1174, 1691], "text": "necropsied"}, {"boundingBox": [1286, 1666, 1317, 1666, 1318, 1689, 1287, 1689], "text": "on"}]}, {"boundingBox": [317, 1694, 438, 1696, 437, 1725, 316, 1724], "text": "July, 2003).", "words": [{"boundingBox": [321, 1696, 367, 1696, 368, 1726, 322, 1725], "text": "July,"}, {"boundingBox": [373, 1696, 436, 1696, 437, 1726, 374, 1726], "text": "2003)."}]}, {"boundingBox": [1158, 1788, 1318, 1787, 1319, 1812, 1159, 1813], "text": "2002/7/24 DSRL", "words": [{"boundingBox": [1161, 1788, 1249, 1789, 1249, 1813, 1160, 1814], "text": "2002/7/24"}, {"boundingBox": [1254, 1789, 1314, 1788, 1314, 1812, 1254, 1813], "text": "DSRL"}]}, {"boundingBox": [145, 1924, 558, 1925, 557, 1953, 144, 1951], "text": "Confidential - Subject to Protective Order", "words": [{"boundingBox": [145, 1924, 259, 1926, 259, 1952, 145, 1952], "text": "Confidential"}, {"boundingBox": [265, 1926, 279, 1926, 279, 1952, 265, 1952], "text": "-"}, {"boundingBox": [284, 1926, 357, 1926, 357, 1952, 285, 1952], "text": "Subject"}, {"boundingBox": [362, 1926, 382, 1927, 382, 1952, 362, 1952], "text": "to"}, {"boundingBox": [387, 1927, 487, 1926, 487, 1952, 388, 1952], "text": "Protective"}, {"boundingBox": [492, 1926, 557, 1926, 557, 1952, 492, 1952], "text": "Order"}]}, {"boundingBox": [1229, 1919, 1485, 1919, 1484, 1946, 1228, 1945], "text": "TAK-THOMCL-00019813", "words": [{"boundingBox": [1231, 1919, 1483, 1921, 1484, 1945, 1232, 1947], "text": "TAK-THOMCL-00019813"}]}, {"boundingBox": [1226, 1951, 1548, 1952, 1547, 1979, 1225, 1978], "text": "Produced in MDL on 09/14/12", "words": [{"boundingBox": [1229, 1953, 1330, 1955, 1330, 1978, 1230, 1978], "text": "Produced"}, {"boundingBox": [1335, 1955, 1356, 1955, 1357, 1978, 1335, 1978], "text": "in"}, {"boundingBox": [1361, 1955, 1412, 1955, 1413, 1978, 1362, 1978], "text": "MDL"}, {"boundingBox": [1417, 1955, 1443, 1955, 1444, 1979, 1418, 1978], "text": "on"}, {"boundingBox": [1448, 1955, 1544, 1952, 1545, 1980, 1449, 1979], "text": "09/14/12"}]}, {"boundingBox": [387, 2196, 1321, 2196, 1321, 2234, 388, 2235], "text": "Source: https://www.indup 2298-ooouts.ucsf.edu/docs/zyjf0226", "words": [{"boundingBox": [388, 2198, 502, 2198, 502, 2234, 388, 2232], "text": "Source:"}, {"boundingBox": [509, 2198, 773, 2199, 773, 2235, 509, 2234], "text": "https://www.indup"}, {"boundingBox": [780, 2199, 1319, 2196, 1320, 2233, 780, 2235], "text": "2298-ooouts.ucsf.edu/docs/zyjf0226", "confidence": "Low"}]}]}]}